drugset / Trial / NCT06423872

A SAD Study of ZT002 Injection in Healthy Participants

NCT06423872

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.

Timeline

Start
2023-06-19
Primary completion
2023-10-20
Completion
2023-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ZT002 Peptide Subcutaneous